Decreasing the Number of MOPP Courses Reduces Gonadal Damage in Survivors of Childhood Hodgkin Disease

Pediatric Blood and Cancer

Volumn 42, Issue 3, 2004, Pages 210-215

  Van Den Berg, H ^a,b   Furstner, F ^a   Van Den Bos, C ^a,b   Behrendt, H ^a,b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Chemotherapy; Gonads; Hodgkins disease; Irradiation; Late effects; Leydig cells; Sertoli cells

Indexed keywords

ABVD PROTOCOL; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MOPP ABV PROTOCOL; MOPP PROTOCOL; MOPP-ABV PROTOCOL; PREDNISONE; PROCARBAZINE; TESTOSTERONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; GONADAL DISEASE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IATROGENIC DISEASE; LEYDIG CELL; MAJOR CLINICAL STUDY; MALE; MENARCHE; OLIGOSPERMIA; ONSET AGE; PATIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SEMEN ANALYSIS; SERTOLI CELL; SURVIVAL; TESTIS SIZE;

EID: 1242294508     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.10422     Document Type: Article

References (52)

1. Lobo-Sanahuja F, Garcia I, Barrantes JC, et al. Pediatric Hodgkin disease in Costa Rica: Twelve years' experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol 1994;22:398-403.
2. Mauch PM, Weinstein H, Botnick L, et al. An evaluation of long-term survival and treatment complications in children with Hodgkin disease. Cancer 1983;51:925-932.
3. Gehan EA, Sullivan MP, Fuller LM, et al. The intergroup Hodgkin disease in children. A study of stages I and II. Cancer 1990;65:1429-1437.
4. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602-1608.
5. Garden AS, Woo SY, Fuller LM, et al. Results of a changing treatment philosophy for children with stage I Hodgkin disease: A 35-year experience. Med Pediatr Oncol 1991;19: 214-220.
6. van den Berg H, Zsiros J, Behrendt H. Treatment of childhood Hodgkin disease without radiotherapy. Ann Oncol 1997;8(Suppl 1): 15-17.
7. Behrendt H, Van Bunningen BN, Van Leeuwen EF. Treatment of Hodgkin disease in children with or without radiotherapy. Cancer 1987;59:1870-1873.
8. Wilimas J, Thompson E, Smith KL. Long-term results of treatment of children and adolescents with Hodgkin disease. Cancer 1980; 46:2123-2125.
9. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin disease: Disease control and long- term complications. Int J Radiat Oncol Biol Phys 1990;18:275-281.
10. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin disease. Med Pediatr Oncol 1996;27:74-78.
11. Kushner BH, Zauber A, Tan CT. Second malignancies after childhood Hodgkin disease. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1988;62:1364-1370.
12. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin disease. N Engl J Med 1996;334:745-751.
13. Shafford EA, Kingston JE, Malpas JS, et al. Testicular function following the treatment of Hodgkin disease in childhood. Br J Cancer 1993;68:1199-1204.
14. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin disease in childhood: The Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873-880.
15. Papadakis V, Vlachopapadopoulou E, Van Syckle K, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol 1999;32:366-372.
16. Willman KY, Cox RS, Donaldson SS. Radiation induced height impairment in pediatric Hodgkin disease. Int J Radiat Oncol Biol Phys 1994;28:85-92.
17. Kadota RP, Burgert EO, Jr., Driscoll DJ, et al. Cardiopulmonary function in long-term survivors of childhood Hodgkin lymphoma: A pilot study. Mayo Clin Proc 1988;63:362-367.
18. Beaty O III, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin disease. J Clin Oncol 1995;13:603-609.
19. Behrendt H, Brinkhuis M, Van Leeuwen EF. Treatment of childhood Hodgkin disease with ABVD without radiotherapy. Med Pediatr Oncol 1996;26:244-248.
20. Ziegler JL, Fass L, Bluming AZ, et al. Chemotherapy of childhood Hodgkin disease in Uganda. Lancet 1972;2:679-682.
21. Ekert H, Waters KD, Smith PJ, et al. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin disease. J Clin Oncol 1988;6:1845-1850.
22. Baez F, Ocampo E, Conter V, et al. Treatment of childhood Hodgkin disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 1997;8:247-250.
23. Aubier F, Flamant F, Brauner R, et al. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol 1989;7:304-309.
24. van den Berg H, Stuve W, Behrendt H. Treatment of Hodgkin disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Med Pediatr Oncol 1997;29:23-27.
25. Gerres L, Bramswig JH, Schlegel W, et al. The effects of etoposide on testicular function in boys treated for Hodgkin disease. Cancer 1998;83:2217-2222.
26. Ekert H, Fok T, Dalla-Pozza L, et al. A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin disease. Br J Cancer 1993;67:159-162.
27. Olweny CL, Katongole-Mbidde E, Kiire C, et al. Childhood Hodgkin disease in Uganda: A ten year experience. Cancer 1978; 42:787-792.
28. Sackmann-Muriel F, Maschio M, Santarelli MT, et al. Results of therapy for Hodgkin disease in childhood. The Argentine Group for treatment of acute leukemia. Cancer Treat Res 1989;41: 271-275.
29. Radford JA, Lieberman BA, Brison DR, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin lymphoma. Lancet 2001;357: 1172-1175.
30. Redman JR, Bajorunas DR, Goldstein MC, et al. Semen cryopreservation and artificial insemination for Hodgkin disease. J Clin Oncol 1987;5:233-238.
31. Fitoussi O, Eghbali H, Tchen N, et al. Semen analysis and cryoconservation before treatment in Hodgkin disease. Ann Oncol 2000;11:679-684.
32. Magnanti M, Malizia S, Garufi G, et al. Luteinizing hormone pulsatility and computer-assisted analysis of sperm features in patients with Hodgkin disease. J Cancer Res Clin Oncol 1996;122: 416-420.
33. Blackball FH, Atkinsons AD, Maaya MB, et al. Semen cryopreservation, utilixation, and reproductive outcome in men treated for Hodgkin disease. Br J Cancer 2002;87:381-384.
34. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkin disease prior to treatment. Ann Oncol 2001;12:1307-1311.
35. Martin RH, Rademaker AW, Leonard NJ. Analysis of chromosomal abnormalities in human sperm after chemotherapy by karyotyping and fluorescence in situ hybridization (FISH). Cancer Genet Cytogenet 1995;80:29-32.
36. Brandriff BF, Meistrich ML, Gordon LA, et al. Chromosomal damage in sperm of patients surviving Hodgkin disease following MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy with and without radiotherapy. Hum Genet 1994;93:295-299.
37. Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin and non-Hodgkin lymphoma. Ann Hematol 1994;68:105-110.
38. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin disease: A preliminary report. J Clin Oncol 1995;13: 1080-1088.
39. Dubey P, Wilson G, Mathur KK, et al. Recovery of sperm production following radiation therapy for Hodgkin disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). Int J Radiat Oncol Biol Phys 2000; 46:609-617.
40. Bonadonna G. Chemotherapy strategies to improve the control of Hodgkin disease: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1982;42:4309-4320.
41. Dhabhar BN, Malhotra H, Joseph R, et al. Gonadal function in prepubertal boys following treatment for Hodgkin disease. Am J Pediatr Hematol Oncol 1993;15:306-310.
42. Clark ST, Radford JA, Crowther D, et al. Gonadal function following chemotherapy for Hodgkin disease: A comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 1995;13: 134-139.
43. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995;13:387-395.
44. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin disease. Cancer Treat Rev 1982;9:21-35.
45. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin disease. Am J Clin Oncol 1997;20:354-357.
46. Bonadonna G, Santoro A, Viviani S, et al. Gonadal damage in Hodgkin disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl 1984;7:140-145.
47. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin disease. Comparative results of MOPP versus ABVD. Eur J Cancer Clin Oncol 1985;21: 601-605.
48. Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin disease with four cycles of ABVD followed by adjuvant radio-therapy: Analysis of efficacy and long-term toxicity. Haematologica 2000;85:1032-1039.
49. Holmes SJ, Whitehouse RW, Clark ST, et al. Reduced bone mineral density in men following chemotherapy for Hodgkin disease. Br J Cancer 1994;70:371-375.
50. Heikens J, Behrendt H, Adriaanse R, et al. Irreversible gonadal damage in male survivors of pediatric Hodgkin disease. Cancer 1996;78:2020-2024.
51. Ben Arush MW, Solt I, Lightman A, et al. A male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000;17:239-245.
52. Pennisi AJ, Grushkin CM, Lieberman E. Gonadal function in children with nephrosis treated with cyclophosphamide. Am J Dis Child 1975;129:315-318.